New promising molecular targets in head and neck squamous cell carcinoma

Julie E. Bauman, Loren S. Michel, Christine H. Chung

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. Recent Findings: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. Summary: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalCurrent Opinion in Oncology
Volume24
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Exome
Therapeutics
DNA Repair
DNA Damage
Tobacco
Carcinoma, squamous cell of head and neck
Survival Rate
Biomarkers
Alcohols
Research
Tumor Hypoxia

Keywords

  • DNA damage repair
  • EGFR
  • HNSCC
  • HPV
  • hypoxia
  • MET
  • NOTCH1
  • PIK3CA
  • TP53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New promising molecular targets in head and neck squamous cell carcinoma. / Bauman, Julie E.; Michel, Loren S.; Chung, Christine H.

In: Current Opinion in Oncology, Vol. 24, No. 3, 05.2012, p. 235-242.

Research output: Contribution to journalArticle

Bauman, Julie E. ; Michel, Loren S. ; Chung, Christine H. / New promising molecular targets in head and neck squamous cell carcinoma. In: Current Opinion in Oncology. 2012 ; Vol. 24, No. 3. pp. 235-242.
@article{80fb2c8dfe854decbf07b05fabc6ee50,
title = "New promising molecular targets in head and neck squamous cell carcinoma",
abstract = "Purpose of Review: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50{\%} in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. Recent Findings: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. Summary: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.",
keywords = "DNA damage repair, EGFR, HNSCC, HPV, hypoxia, MET, NOTCH1, PIK3CA, TP53",
author = "Bauman, {Julie E.} and Michel, {Loren S.} and Chung, {Christine H.}",
year = "2012",
month = "5",
doi = "10.1097/CCO.0b013e3283517920",
language = "English (US)",
volume = "24",
pages = "235--242",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - New promising molecular targets in head and neck squamous cell carcinoma

AU - Bauman, Julie E.

AU - Michel, Loren S.

AU - Chung, Christine H.

PY - 2012/5

Y1 - 2012/5

N2 - Purpose of Review: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. Recent Findings: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. Summary: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.

AB - Purpose of Review: Despite advances in multimodality therapy, the overall 5-year survival rate is 40-50% in patients with head and neck squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities. This review highlights promising targets with the potential to improve clinical outcomes in HNSCC. Recent Findings: In addition to mutagenic exposure to tobacco and alcohol as risk factors, recent studies have shown that human papillomavirus is one of the main causes of HNSCC and as such is being investigated as a therapeutic target. Furthermore, recent data generated from whole exome sequencing of HNSCC, new insights into the biology of DNA damage repair, and increased understanding of tumor hypoxia responses are pointing to new therapeutic possibilities for treating HNSCC. Summary: HNSCC is a heterogeneous disease. Improved treatment will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.

KW - DNA damage repair

KW - EGFR

KW - HNSCC

KW - HPV

KW - hypoxia

KW - MET

KW - NOTCH1

KW - PIK3CA

KW - TP53

UR - http://www.scopus.com/inward/record.url?scp=84859813676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859813676&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e3283517920

DO - 10.1097/CCO.0b013e3283517920

M3 - Article

C2 - 22327839

AN - SCOPUS:84859813676

VL - 24

SP - 235

EP - 242

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -